MedTrace Logo

Study to Evaluate the Safety and Activity of BB3 to Treat Heart Attack

NCT01539590 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2014-11-21

Study results available
· View outcomes & findings →

Summary

The study will evaluate the effect of BB3 to preserve myocardial (heart) tissue and function following myocardial infarction (heart attack).

Conditions

Interventions

DRUG

BB3

Daily intravenous administration of 2 mg/kg BB3 for four (4) days

DRUG

Normal saline

Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Angion Biomedica Corp

    lead INDUSTRY

Principal Investigators

  • Weizhong Cai · Sponsor GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-07-31
Completion
2013-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01539590 on ClinicalTrials.gov